跳至主要内容
临床试验/CTIS2022-502502-32-00
CTIS2022-502502-32-00招募中1 期

Safety of ibuprofen after major orthopaedic surgeries - the PERISAFE randomized clinical multicentre trial

Slagelse Hospital0 个研究点目标入组 2,904 人开始时间: 2022年12月14日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
2,904

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Scheduled for planned primary hip or knee arthroplasty, including hemiarthroplasty., Age = 18 years., Planned perioperative pain treatment with NSAID, decided by the clinical doctor., Negative urine Human Chorionic Gonadotropin (hCG) pregnancy test and use of anti-conception for women in fertile age., Written informed consent.

排除标准

  • Patients unable to understand or speak Danish., Allergy to, or contraindications against ibuprofen, including heart insufficient (NYHA IV), severe thrombocytopenia (< 50 x 10^9/l), asthma triggered by NSAID, or known renal impairment (eGFR < 60 ml/min), previous ulcer due to NSAID treatment.

研究者

发起方
Slagelse Hospital

相似试验

Safety of ibuprofen after major orthopaedic surgeries | 临床试验